Form 4: Edgewise Therapeutics CMO Joanne M. Donovan Reports Stock Transactions
SEC Form 4 Filing
Joanne M. Donovan, CMO of Edgewise Therapeutics, reports the acquisition and disposition of common stock and restricted stock units to cover tax obligations.
Summary
- On May 1, 2025, Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics, acquired 10,417 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- On May 2, 2025, Donovan sold 5,187 shares of common stock at an average price of $16.4542 per share.
- The sale was to cover statutory tax withholding obligations related to the RSU vesting.
- Following these transactions, Donovan beneficially owns 21,588 shares of Edgewise Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Industry Context
This Form 4 filing is a routine disclosure related to stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares, but the impact is likely minimal as it is related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/03/2021 | Date of Power of Attorney execution. |
| 05/01/2025 | Acquisition of 10,417 shares of common stock through RSU vesting. |
| 05/01/2025 | Date Restricted Stock Units were exercisable. |
| 05/02/2025 | Sale of 5,187 shares of common stock at an average price of $16.4542. |
| 05/07/2025 | Date of Form 4 signature. |
Keywords
Form 4, Section 16, EWTX, Edgewise Therapeutics, Donovan Joanne M., CMO, Stock Transaction, Restricted Stock Units, RSU, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.